ABT-869, ABT869, Linifanib, AL-39324, RG3635
Availability: In Stock
Alternative Names: ABT-869, ABT869, AL-39324, RG3635
ABT-869 (Linifanib) is a potent, selective inhibitor of the VEGF and PDGF platelet-derived growth factor families of RTKs. ABT-869 is being studied in advanced renal cell cancer (RCC), advanced solid tumors, advanced hepatocellular carcinoma (HCC) and non small cell lung cancer (NSCLC).
Compound is also called Linifanib, AL-39324, RG3635